Sarah Dobrozsi1, Ke Yan2, Raymond Hoffmann2, Julie Panepinto1,2. 1. Department of Pediatric Hematology/Oncology, The Medical College of Wisconsin, Wisconsin. 2. Quantitative Health Sciences, Children's Research Institute of the Children's Hospital of Wisconsin, Milwaukee, Wisconsin.
Abstract
BACKGROUND: Changes in patient function and factors affecting pediatric patients with cancer during treatment are largely unknown. The purpose of this study was to measure patient-reported outcomes (PROs) in children during the initial 6 months of therapy to characterize function and explore factors associated with function including type of cancer, intensity of therapy, age, and gender. PROCEDURE: We conducted a prospective cohort study of children aged 5-21 newly diagnosed with cancer. PROs were obtained twice monthly over the first 6 months of treatment. The Patient-Reported Outcome Measurement Information System (PROMIS) was used to measure patient mobility, fatigue, pain interference, peer relationships, anxiety, and depressive symptoms. A generalized linear mixed model was used to analyze changes by domain over time. RESULTS: Forty patients completed the study with a mean age of 11.7 years (standard deviation [SD] 4.7), 60% had leukemia/lymphoma. All patients report improved pain over time (P = 0.008). Patients with central nervous system (CNS)/solid tumor report better mobility (P < 0.001), less fatigue (P < 0.001), less pain (P < 0.001), less anxiety (P < 0.001), fewer depressive symptoms (P < 0.001), and better peer relationships (P = 0.0036). Younger patients report worse mobility (P = 0.017), more fatigue (P = 0.032), more pain (P < 0.001), more anxiety (P = 0.017), and more depressive symptoms (P = 0.005). CONCLUSIONS: Pain improved for all patients over the first 6 months of cancer treatment. Age and tumor type also affected patient-reported function for all domains. Understanding the burden of cancer treatment is critical to refine supportive care interventions to minimize the burden of pediatric cancer treatment.
BACKGROUND: Changes in patient function and factors affecting pediatric patients with cancer during treatment are largely unknown. The purpose of this study was to measure patient-reported outcomes (PROs) in children during the initial 6 months of therapy to characterize function and explore factors associated with function including type of cancer, intensity of therapy, age, and gender. PROCEDURE: We conducted a prospective cohort study of children aged 5-21 newly diagnosed with cancer. PROs were obtained twice monthly over the first 6 months of treatment. The Patient-Reported Outcome Measurement Information System (PROMIS) was used to measure patient mobility, fatigue, pain interference, peer relationships, anxiety, and depressive symptoms. A generalized linear mixed model was used to analyze changes by domain over time. RESULTS: Forty patients completed the study with a mean age of 11.7 years (standard deviation [SD] 4.7), 60% had leukemia/lymphoma. All patients report improved pain over time (P = 0.008). Patients with central nervous system (CNS)/solid tumor report better mobility (P < 0.001), less fatigue (P < 0.001), less pain (P < 0.001), less anxiety (P < 0.001), fewer depressive symptoms (P < 0.001), and better peer relationships (P = 0.0036). Younger patients report worse mobility (P = 0.017), more fatigue (P = 0.032), more pain (P < 0.001), more anxiety (P = 0.017), and more depressive symptoms (P = 0.005). CONCLUSIONS:Pain improved for all patients over the first 6 months of cancer treatment. Age and tumor type also affected patient-reported function for all domains. Understanding the burden of cancer treatment is critical to refine supportive care interventions to minimize the burden of pediatric cancer treatment.
Authors: Nils D Arvold; Terri S Armstrong; Katherine E Warren; Susan M Chang; Lisa M DeAngelis; Jaishri Blakeley; Marc C Chamberlain; Erin Dunbar; Herbert H Loong; David R Macdonald; David A Reardon; Michael A Vogelbaum; Ying Yuan; Michael Weller; Martin van den Bent; Patrick Y Wen Journal: Neuro Oncol Date: 2018-06-18 Impact factor: 12.300
Authors: David T W Jones; Mark W Kieran; Eric Bouffet; Sanda Alexandrescu; Pratiti Bandopadhayay; Miriam Bornhorst; David Ellison; Jason Fangusaro; Michael J Fisher; Nicholas Foreman; Maryam Fouladi; Darren Hargrave; Cynthia Hawkins; Nada Jabado; Maura Massimino; Sabine Mueller; Giorgio Perilongo; Antoinette Y N Schouten van Meeteren; Uri Tabori; Katherine Warren; Angela J Waanders; David Walker; William Weiss; Olaf Witt; Karen Wright; Yuan Zhu; Daniel C Bowers; Stefan M Pfister; Roger J Packer Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: Allison Barz Leahy; Lisa A Schwartz; Yimei Li; Bryce B Reeve; Justin E Bekelman; Richard Aplenc; Ethan M Basch Journal: Cancer Date: 2021-05-04 Impact factor: 6.921
Authors: Angela Steineck; Miranda C Bradford; Nancy Lau; Samantha Scott; Joyce P Yi-Frazier; Abby R Rosenberg Journal: Children (Basel) Date: 2019-11-02